Market Newsdesk

BOCA RATON, Fla. , Feb. 19, 2025 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Denver Metro Association of REALTORS^® (“DMAR”) will offer FOREWARN^® services to its 7,000+ members it serves throughout the Denver metropolitan area to promote proactive real estate agent safety.

Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients — using just a phone number. FOREWARN allows agents to properly and safely plan for showings with a higher level of confidence.

The FOREWARN services offered by DMAR are available to the 7,000+ members at no additional cost to individual agents.

“Protecting our members and equipping them with the right resources is at the core of our mission,” stated Brendan Bailey, CEO of Denver Metro Association of REALTORS^®. “With the evolving challenges in safety and fraud prevention, providing FOREWARN was a natural step. This powerful solution offers real-time identity verification, giving our members the confidence and security they need to navigate their daily business with peace of mind.”

Existing DMAR members will receive specific instructions on how to move forward with activating their FOREWARN subscription as an included benefit.

All other real estate agencies, agents, and appraisers can learn more about FOREWARN at www.forewarn.com.

About FOREWARN^®

At FOREWARN, we bring instant knowledge through innovative solutions to ensure safer engagements and smarter interactions. Leveraging powerful analytics and a massive data repository, our solutions enable organizations to gain real-time knowledge, for purposes such as verifying identity, searching for criminal histories, and validating information. Risk assessment and due diligence at your fingertips™.

RELATED LINKS:

www.forewarn.com

About red violet^®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our intelligent platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, to ensure safety, and to reduce fraud and the concomitant expense borne by society. For more information, please visit www.redviolet.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether FOREWARN will address critical safety and security areas for Denver Metro Association of REALTORS^® members and whether FOREWARN will give Denver Metro Association of REALTORS^® members the confidence and security they need to navigate their daily business with peace of mind. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Camilo Ramirez
Red Violet, Inc.
561-757-4500
[email protected]

The Brera Strumica team against Pelister in the Macedonian First Football League, on February 16, 2025

Dublin, Ireland and Strumica, North Macedonia, Feb. 19, 2025 (GLOBE NEWSWIRE) — Following the winter 2024-25 transfer window, Brera Holdings PLC’s (Nasdaq: BREA) portfolio clubs in North Macedonia, Brera Strumica and Brera Tiverija, are pleased to announce several exciting signings that they believe will strengthen their squads ahead of the spring championship. These additions reflect the clubs’ ongoing commitment to player development and the expansion of their talent pathways, particularly from Africa and Eastern Europe.

Brera Strumica (Men’s Team)

• Fodey Travali (Midfielder) – A 23-year-old former youth national team player for Gambia, with experience in Cyprus, Turkey, and Estonia
• Dragan Bilbia (Defender) – A 22-year-old Bosnian defender, formerly with Radički Srem and Rudar Prijedor, and a youth international for Bosnia
• Fahd Nzengue (Forward) – A 24-year-old Gabonese forward with experience in Slovenia’s first and second divisions
• Hadji Drame (Right Wing) – A 24-year-old Mali-born winger with a history in Estonia, Georgia, and Armenia
• Filip Mihailov (Midfielder/Attacker) – A 26-year-old versatile player with experience in North Macedonia and Austria, returning to Brera Strumica for the spring season
• Zoran Ivanovski (Wing) – A 24-year-old winger with experience in North Macedonia’s top leagues, returning to Brera Strumica for the spring season
• Hristijan Jankuloski (Defender) – A 23-year-old Macedonian defender with previous experience in Australia and Macedonia
• Mihail Milevski (Midfielder/Defender) – A 22-year-old versatile player from Bitola, North Macedonia, joining from FK Novaci in North Macedonia

Brera Tiverija (Women’s Team)

• Christine Nafula (Forward) – A 33-year-old Kenyan forward with extensive experience in Africa, Europe, and Turkey, bringing international flair to Brera Tiverija’s attack
• Danche Karpuzovska (Midfielder/Forward) – A 22-year-old from Strumica, returning after playing for ZFK Plackovica, ZFK Vardar, and ZFK Ljuboten

Brera Tiverija’s women’s team is currently top of the league and proudly holds the title of “winter champions,” showcasing their strength and determination. The team expects the addition of Nafula and Karpuzovska to further solidify their already impressive squad as they aim to maintain their position at the top in the spring.

Both Brera Strumica and Brera Tiverija are proud to continue developing player pathways from Africa and Eastern Europe, reinforcing their commitment to building competitive squads with diverse international talent. These new signings are expected to bring fresh energy and expertise, positioning the teams for a successful second half of the season.

ABOUT BRERA HOLDINGS PLC

Brera Holdings PLC (Nasdaq: BREA) is dedicated to expanding its social impact football business by developing a global portfolio of emerging football and sports clubs. Building on the legacy of Brera FC, which it acquired in 2022, the Company aims to create opportunities for tournament prizes, sponsorships, and professional consulting services. Brera FC, recognized as “The Third Team of Milan,” has been crafting an alternative football legacy since its founding in 2000. The club also organizes the FENIX Trophy, a nonprofessional pan-European tournament acknowledged by UEFA. This tournament, which has been referred to as “the Champions League for Amateurs” by BBC Sport, has garnered significant media coverage, including from ESPN.

In its efforts to broaden its reach, Brera expanded into Africa in March 2023 by establishing Brera Tchumene FC in Mozambique, which quickly rose to the First Division after winning its post-season tournament. In April 2023, the Company acquired a 90% stake in the North Macedonian first-division team Fudbalski Klub Akademija Pandev, now known as Brera Strumica FC. Additionally, in June 2023, Brera made a strategic investment in Manchester United PLC, realizing a 74% gain. The Company has further diversified its portfolio by acquiring a majority stake in UYBA Volley, an Italian women’s professional volleyball team, in July 2023, assuming control of Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team, which became Brera Ilch FC, in September 2023, and establishing a joint stock company for the North Macedonian women’s football club Tiverija Strumica, now known as Brera Tiverija FC, a wholly-owned subsidiary of Brera Strumica FC, in June 2024.

On December 31, 2024, Brera signed of an agreement to acquire majority ownership of SS Juve Stabia srl, an Italian Serie B football club known as “The Second Team of Naples,” which will be conducted in a multi-step process, and marks a significant expansion of the Company’s MCO model.  As of February 12, 2025, Brera holds a 38.46% equity ownership interest in Juve Stabia, currently in a playoff-qualifying sixth place position in the Serie B standings.  With a strategic emphasis on bottom-up value creation, innovation-driven growth, and socially impactful outcomes, Brera Holdings has established itself as a forward-thinking leader in the global sports industry. For more information, visit www.breraholdings.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, the popularity and/or competitive success of the Company’s acquired football and other sports teams, the Company’s ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company’s ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Company Contact Information:

Dan McClory, Executive Chairman, Brera Holdings PLC
Email: [email protected]

Attachment

• The Brera Strumica team against Pelister in the Macedonian First Football League, on February 16, 2025

MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) — Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).

The patent, once issued on U.S. Patent Application No.: 17/865,697, covers the repeat dose regimen used in the RAPID Phase 3 study that evaluated CARDAMYST in PSVT and proposed for the package insert as part of the CARDAMYST New Drug Application (NDA) currently under review by the U.S. Food and Drug Administration (FDA). The issuance of the Notice of Allowance potentially extends our intellectual property protection for CARDAMYST in the United States until July 2042, which is an additional 6 years of potential protection for our intellectual property portfolio.

“This added protection will position us to optimize the commercial value of CARDAMYST,” said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. “The new patent underscores Milestone’s continued development of our patent portfolio and our commitment to innovation in cardiology.”

The repeat dose regimen, proposed in the NDA for CARDAMYST, directs the patient to administer a second 70 mg dose of CARDAMYST should the patient continue to experience symptoms from their PSVT episode ten minutes after their initial dose.

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations to support the anticipated launch in mid-2025. The CARDAMYST brand name is conditionally approved by the FDA.

About Etripamil

Etripamil is Milestone’s lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the timing and outcomes of future interactions with the FDA, including the PDUFA target date; the potential extension of protection under our intellectual property portfolio; the potential of etripamil to provide health care providers with a new treatment option to enable on-demand care and patient self-management and provide patients with active management and a greater sense of control over their condition. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2023, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings Milestone may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Kim Fox, Vice President, Communications, [email protected]

Investor Relations

Chris Calabrese, [email protected]
Kevin Gardner, [email protected]

ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) — Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today announces the rebranding of FCF Advisors to Abacus FCF Advisors, a subsidiary of ABL Wealth.

This rebrand highlights the manager’s position as a leader in free cash flow investing and analytics by pioneering the FCF Leaders Model, which serves as the foundation for the firm’s quantitative investment process that identifies the most profitable companies. As part of the rebrand, Abacus FCF Advisors announced the launch of the Abacus FCF Small Cap Leaders ETF (ticker: ABLS), and management fee reductions of 5-10 basis points across all ETFs. An 18-month fee waiver of 20 basis points was also introduced on four of the ETFs.

Ticker	Fund Name
ABFL	Abacus FCF Leaders ETF
ABLG	Abacus FCF International Leaders ETF
ABLD	Abacus FCF Real Assets Leaders ETF*
ABOT	Abacus FCF Innovation Leaders ETF*
ABLS	Abacus FCF Small Cap Leaders ETF*
ABHY	Abacus Tactical High Yield ETF*

*Effective 2/1/2025, a fee waiver of 20 basis points will be offered to these funds for 18 months.

To celebrate this iconic event, the Abacus FCF Advisors team, along with other executives from ABL Wealth, is ringing the Cboe Global Markets Exchange opening bell today, Wednesday, February 19, 2025.

“We are thrilled to ring the Cboe bell,” said Jay Jackson, CEO of Abacus Life. “The FCF acquisition, including the rebranded funds and new ETF, constitute significant milestones in Abacus’ ongoing expansion of ABL Wealth and its suite of innovative products, as well as our goal of delivering comprehensive, lifespan-based financial advisory services and products. FCF aligns perfectly with our strategy of providing clients with holistic and tailored financial solutions throughout their lives.”

About Abacus FCF Advisors

Abacus FCF Advisors is a leader in free cash flow investing and analytics, having pioneered the Free Cash Flow Leaders Model, which serves as the foundation for the firm’s quantitative investment process. Based on our research for the past decade, constructing a high-conviction portfolio through comprehensive analysis of Free Cash Flow Return on Invested Capital has historically outperformed and delivered superior long-term capital growth. This model prioritizes prudent capital expenditure, low accruals, high cash flow margins, and strong asset turnover. Abacus FCF Advisors has a suite of core and thematic free cash flow equity strategies and offers over 50 customizable free cash flow index strategies covering 8 global equities allocation categories available in ETFs, SMA/white label SMA and model delivery.

www.abacusfcf.com

About Abacus

Abacus is a pioneering global alternative asset manager and market maker specializing in uncorrelated financial products. The company leverages its proprietary, cutting-edge longevity data and actuarial technology to purchase life insurance policies from consumers seeking liquidity. This creates a high-return asset class uncorrelated to market fluctuations for institutional investors.

With nearly $3 billion in assets under management, including recently-completed acquisitions, Abacus is the only publicly traded global alternative asset manager focused on lifespan-based financial products.

Abacus is expanding its leading expertise in longevity and lifespan into new growth areas:

• ABL Wealth – Leverages decades of data and proprietary algorithms to offer longevity-based wealth management platforms that enable financial advisors to create customized plans and provide access to uncorrelated investments.
• ABL Tech – A groundbreaking technology service that delivers advanced real-time data tracking and analysis for pension funds, governments, insurance companies, retirement associations, and more.

Through each new channel, Abacus is revolutionizing the future of asset management and financial planning, centered on longevity and lifespan.

www.Abacuslife.com

Contacts:

ABL Wealth

Fei Xue, CAIA – Vice President, ABL Wealth
[email protected]
(321) 710-5957

Abacus Life Investor Relations

Robert F. Phillips – SVP Investor Relations and Corporate Affairs
[email protected]
(321) 290-1198

David Jackson – IR/Capital Markets Associate
[email protected]
(321) 299-0716

Abacus Life Public Relations


[email protected]

Important Information:

Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the statutory and summary prospectuses, a copy of which may be obtained by visiting the Fund’s website at www.abacusfcf.com/ABFL, www.abacusfcf.com/ABLG, www.abacusfcf.com/ABLD, www.abacusfcf.com/ABOT,  www.Abacusfcf.com/ABLS, www.Abacusfcf.com/ABHY. Please read the prospectus or summary prospectus, if available, carefully before you invest.

Investing involves risk, including possible loss of principal.

Free Cash Flow (FCF) represents the cash that a company is able to generate after accounting for capital expenditures.

Distributed by Quasar Distributors, LLC. Quasar is not related to Abacus or ABL.

American Rebel Light to be served at Knoxville Raceway the “Sprint Car Capital of the World” and the Dingus Lounge “Iowa’s Most Notorious Bar”

Nashville, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), proudly announces its strategic expansion into Iowa through a partnership with Mahaska Bottling Company (mahaska.com). This move is a significant milestone in the Company’s broader Midwest growth strategy, underscoring Iowa’s pivotal role as a key market in American Rebel’s regional expansion.

“I had a hunting show, Maximum Archery World Tour, on television for ten years. I bowhunted all over the world, but in Iowa I’ve met some of the most passionate hunters and outdoorsmen I’ve ever met. I’ve done several “meet and greets” at the Iowa Deer Classic in Des Moines over the years and it was always a lot of fun and great to meet everyone there. Getting American Rebel Light Beer distributed throughout the state of Iowa really means a lot to me,” said American Rebel CEO Andy Ross.

Powerful Iowa Distribution Partnership – Mahaska Bottling Company and Rebel Light

Founded in 1889, Mahaska Bottling Company boasts a rich history of providing high-quality beverage distribution services across Iowa. Their extensive network and dedication to customer satisfaction make them an ideal partner for American Rebel Beer.

The agreement with Mahaska Bottling Company will allow American Rebel Light Beer to captivate a broader audience in Iowa, introducing its Premium Light Lager to beer enthusiasts across the region. This partnership aims to provide a seamless distribution network, ensuring American Rebel Light Beer is available in local bars, restaurants, and retail outlets. “We are very excited to bring American Rebel Light to our valued customers in the State of Iowa,” said Chad Irving, Chief Marketing Officer of Mahaska Bottling Company.

“We are thrilled to partner with Mahaska Bottling Company to bring American Rebel Light Beer to Iowa,” said Todd Porter, President of American Rebel Beverages. “This collaboration allows us to serve the patriotic consumers in Iowa who are looking for a clean, natural, and great-tasting light beer that embodies the values of our great nation.”

Launch Events to bring American Rebel Light Beer to Iowa’s Best Venues

American Rebel Beer will host a series of exciting events, including beer tastings, live music performances, and promotional giveaways. The festivities will kick off this Spring and run through the Fall, offering a perfect opportunity for the community to come together and enjoy America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, STAND YOUR GROUND BEER!

American Rebel Light will be anchored by two legendary Iowa establishments:

• the Knoxville Raceway (knoxvilleraceway.com) and
• the Dingus Lounge (www.dinguslounge.com)

“The Knoxville Raceway and the Dingus Lounge will put Rebel Light on the map in Iowa right out of the box,” said American Rebel CEO Andy Ross. “And Mahaska Bottling Company and our Rebel Light Street Team will carry our message throughout the rest of the state utilizing our Rebel Light nights in bars and restaurants across the state.

The Knoxville Raceway is known as the “Sprint Car Capital of the World” and the home of the Knoxville Nationals, a premier sprint car racing event that draws tens of thousands of fans each year that was first held in 1961.

“We have been looking forward to getting American Rebel Light in here for a while,” said Knoxville Raceway General Manager Jason Reed. “It’s a great fit for our audience. We love what American Rebel is doing in motor sports and we look forward to supporting them.”

The Knoxville Raceway seats around 21,000, which is thought to be the fourth largest outdoor facility in Iowa behind the football stadiums of Iowa and Iowa State University and the Iowa Speedway. To promote American Rebel Light at the Raceway, entertainment events headlined by American Rebel CEO Andy Ross are in the works. American Rebel and Tony Stewart Racing will collaborate on further promotional value through the American Rebel sponsorship of the Tony Stewart Racing NHRA Funny Car driven by Matt Hagan and Tony Stewart’s love of sprint car racing and Tony’s suite at the Knoxville Raceway.

“Iowa’s Most Notorious Bar”, the Dingus Lounge, is the ideal establishment to serve American Rebel Light. Owner AJ Mottet has expanded Dingus again and again. He now owns the entire block and during the Knoxville Nationals he’ll pack every square foot with patriotic race fans who love beer

“Dingus Lounge is excited and proud to be a part of American Rebel Beer,” said AJ Mottet. “The World’s Best Racing Bar and our patrons stand for the same core values that American Rebel represents. Freedom has a price, that price is the sacrifice many men and women who gave everything for us to be the land of the free. Dingus and American Rebel Beer honor those who sacrificed. We honor them every day. It’s who we are.”

“I LOVE THAT BAR,” said Andy Ross. “I would love to play at the Dingus Lounge during the Knoxville Nationals. That would be a great date to add to our tour this summer. It’s definitely our crowd and I think it would be a blast.”

During the Thursday of a previous Knoxville Nationals Dingus claims it sold 10,700 cans of Busch Light alone. “We had a chain of employees handing cases right from the truck through the crowd, right into the bar tubs,” Mottet says. “If they can love the dirt in their track, then they can love the dive in their bar.”

For more information about the launch events and American Rebel Beer, please visit (americanrebelbeer.com) or follow us on our social media platforms.

About Mahaska Bottling Company

Mahaska Bottling Company is a 7th generation family-owned bottling and distribution company that has been around for more than 135 years. From its early years at the dawn of the soft-drink industry, Mahaska has expanded its portfolio and added a multitude of product and service lines across non-alcoholic beverages, coffee, food, snacks, and beer.

About American Rebel Light Beer

Produced in partnership with AlcSource, American Rebel Light Beer (americanrebelbeer.com) is a premium domestic light lager celebrated for its exceptional quality and patriotic values. It stands out as America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer.

American Rebel Light is a Premium Domestic Light Lager Beer – All Natural, Crisp, Clean and Bold Taste with a Lighter Feel. With approximately 100 calories, 3.2 carbohydrates, and 4.3% alcoholic content per 12 oz serving, American Rebel Light Beer delivers a lighter option for those who love great beer but prefer a more balanced lifestyle. It’s all natural with no added supplements and importantly does not use corn, rice, or other sweeteners typically found in mass produced beers.

About American Rebel Holdings, Inc.

American Rebel Holdings, Inc. (NASDAQ: AREB) has operated primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products and has recently transitioned into the beverage industry through the introduction of American Rebel Light Beer. The Company also designs and produces branded apparel and accessories. To learn more, visit www.americanrebel.com and www.americanrebelbeer.com. For investor information, visit www.americanrebel.com/investor-relations.

Media Inquiries:
Matt Sheldon
[email protected]
917-280-7329

American Rebel Holdings, Inc.
[email protected]

American Rebel Beverages, LLC
Todd Porter, President
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. American Rebel Holdings, Inc., (NASDAQ: AREB; AREBW) (the “Company,” “American Rebel,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include benefits of marketing outreach efforts, actual placement timing and availability of American Rebel Beer, success and availability of the promotional activities, our ability to effectively execute our business plan, and the Risk Factors contained within our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2023. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:
[email protected]
[email protected]

Attachment

• American Rebel Holdings Inc

PERTH, Australia, Feb. 19, 2025 (GLOBE NEWSWIRE) — Locafy Limited(Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized leader in location based digital marketing solutions, with market leading SEO capabilities, recently participated in two investor-focused presentations, highlighting its latest business developments and strategic initiatives.

Breakout Investors Presentation with Fathom Holdings (NASDAQ: FTHM)

Locafy CEO Gavin Burnett joined Breakout Investors alongside Fathom Holdings CEO Marco Fregenal to discuss their partnership, which is designed to enhance real estate professionals’ digital presence through advanced SEO solutions. The collaboration leverages Locafy’s proprietary Localizer technology to help real estate agents and brokerages improve their search engine rankings, attract more leads, and convert online visibility into business growth.

During the presentation, Locafy and Fathom Holdings provided insights into how Locafy’s innovative SEO technology is supporting Fathom’s rapidly expanding network of real estate professionals. The discussion covered the integration of Locafy’s local SEO solutions into Fathom’s existing technology ecosystem, driving increased visibility and engagement for agents and clients.

A recording of the presentation and further details are available on the Breakout Investors platform here.

Locafy Featured on Planet MicroCap Podcast

Locafy was also recently featured on the Planet MicroCap Podcast, hosted by Robert Kraft, where Burnett discussed the Company’s latest advancements and growth strategies.

During the interview, Burnett provided insights into:

• Locafy’s Competitive Edge: How its proprietary local SEO technology is helping businesses secure Page 1 Google rankings with minimal effort.
• Growth Strategy & Market Expansion: The Company’s capital-efficient approach to scaling its operations and revenue.
• Recent Partnerships & Industry Impact: Including the collaboration with Fathom Holdings to enhance the real estate sector’s digital presence.
• AI & SEO Innovations: The increasing role of AI-driven search and how Locafy is positioning itself at the forefront of the industry’s evolution.

The full podcast episode can be accessed here.

Locafy will be attending the Planet MicroCap Showcase: VEGAS 2025 being held April 22-24, 2025 at the Paris Hotel & Casino in Las Vegas, NV. Investors interested in scheduling a one-on-one meeting with Locafy management can contact Locafy’s investor relations team at [email protected].

“We appreciate the opportunity to engage with the investment community and showcase how Locafy’s technology is driving real business impact,” said Burnett. “Our partnership with Fathom Holdings highlights the increasing demand for effective local SEO solutions in the real estate sector, and our conversation on Planet MicroCap allowed us to share how we’re positioning Locafy for sustained growth.”

For more information about Locafy’s technology, including educational blogs and case studies, please visit Locafy’s investor relations website at investor.locafy.com.

About Locafy

Locafy (Nasdaq: LCFY, LCFYW) is a globally recognized software-as-a-service technology company specializing in local search engine marketing. Founded in 2009, Locafy’s mission is to revolutionize the US$700 billion SEO sector. We help businesses and brands increase search engine relevance and prominence in a specific proximity using a fast, easy, and automated approach. For more information, please visit www.locafy.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, although not all forward-looking statements contain these words. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 20-F, filed with the SEC on November 12, 2024, as amended, and available on its website (

www.sec.gov

). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations Contact

Matt Glover
Gateway Group, Inc.
(949) 574-3860
[email protected] 

Shenzhen, China, Feb. 19, 2025 (GLOBE NEWSWIRE) — Top KingWin Ltd (“Top KingWin” or the “Company”) (Nasdaq: WAI) today announced that on February 18, 2025, it entered into a securities purchase agreement (the “SPA”) to issue a convertible note in the original principal amount of $1,000,000 (the “Note”) to an institutional investor (the “Purchaser”), convertible into its class A ordinary shares, par value of $0.0001 per share (the “Ordinary Shares”), for gross proceeds of $900,000 (the “Offering”).

R.F. Lafferty & Co., Inc. acted as the Company’s exclusive placement agent for this Offering.

The Note bears interest at a rate of 11.75% per annum, subject to adjustment from time to time in accordance with the terms of the Note. All outstanding principal and accrued interest on the Note will become due and payable twelve months after the issuance of the Note (“Issuance Date”), and the Purchaser has the option to extend the maturity term for another twenty-four months upon mutual agreement of the Company and the Purchaser. The Note includes an original issue discount of 10%. The Company may not prepay any portion of the outstanding principal, accrued and unpaid interest or accrued and unpaid late charges on principal and interest, if any. At any time after the Issuance Date, the Note is convertible into validly issued, fully paid and non-assessable Ordinary Shares, on the terms and conditions set forth in the Note. Upon the occurrence of an Event of Default, as defined in the Note, the Purchaser may require the Company to redeem all or any portion of the Note by delivering written notice thereof.

The Note will be issued to the Purchaser upon satisfaction of all closing conditions. The issuance of the Ordinary Shares issuable upon conversion of the Notes is pursuant to a shelf registration statement on Form F-3, as amended (File No. 333-283030), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 13, 2024.

Subject to the terms and conditions set forth in the SPA, the Purchaser and the Company plan to participate in seven additional tranches of closings for the purchase by such Purchaser, and the sale by the Company, including (i) six tranches of a Note (or Notes) in an aggregate original principal amount of up to $4,000,000 each, and (ii) one tranche of a Note (or Notes) in an aggregate original principal amount of up to $4,500,000, as set forth in the Schedule of Buyers to the SPA, with the aggregate original principal amount of these additional closings up to $28,500,000.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Top KingWin Ltd

Top KingWin’s main clients are entrepreneurs and executives in small and medium-sized enterprises in China. Services provided by Top KingWin to its clients including (i) corporate business training services, which mainly focus on providing training services of advanced knowledge and new perspectives on the capital markets, (ii) corporate consulting services, which mainly focus on providing a combination of customized corporate consulting services to fulfill client’s unique financial needs, and (iii) advisory and transaction services, which mainly focus on connecting entrepreneurs and businesses with diversified sources of capital. Its mission is to provide comprehensive services to address clients’ needs throughout all phases of their development and growth.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact in this press release are forward-looking statements, including but not limited to, the use of proceeds from the Company’s offering, the intent, belief or current expectations of Top KingWin and members of its management, as well as the assumptions on which such statements are based. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Bonnie

Email: [email protected]

Key Focus Areas for Jesse Thomas:

• 
  Build & Launch BranchOut’s DTC Website
  
• 
  Expand Product Line onto Amazon & other DTC Platforms
  
• 
  Develop & Grow Email Subscription Program
  
• 
  Launch Wholesale Portal for Independent Retailers
  
• 
  Oversee Digital Advertising & Social Media Strategy
  
  

BEND, Ore., Feb. 19, 2025 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a pioneer in the patented GentleDry™ dehydration technology, today announces the appointment of Jesse Thomas as its Chief Brand Officer. In this role, Thomas will lead the company’s brand and marketing strategy, with a particular focus on expanding BranchOut’s direct-to-consumer (DTC) business, complementing its rapidly growing branded retail, private label and industrial ingredient channels.

Thomas, best known as the Founder & CEO of Picky Bars, brings a proven track record of scaling DTC brands from concept to acquisition. Under his leadership, Picky Bars became a household name in the health and performance snack space, growing a 10,000+ subscriber base and establishing a multimillion-dollar e-commerce business that culminated in its $12M acquisition by Laird Superfood.

As BranchOut continues its rapid retail expansion in warehouse clubs, major grocery chains, and ingredient markets, Thomas will spearhead high-margin, recurring revenue streams in e-commerce, subscription models, and direct brand engagement.

Beyond his business acumen, Thomas is an accomplished professional athlete, having competed as an elite triathlete and Ironman champion. His deep connection to performance nutrition, active lifestyles, and consumer engagement has shaped his approach to brand building and DTC. This background makes him uniquely positioned to drive BranchOut’s mission of delivering nutrient-dense, clean-label snacks that support active and health-conscious consumers.

Eric Healy, CEO of BranchOut Food, expressed enthusiasm about the new hire: “Jesse’s proven track record in building and scaling DTC brands is exactly what we need as we expand our direct-to-consumer presence. His ability to connect with consumers, craft compelling brand narratives, and drive growth through digital channels will be instrumental in our next phase of expansion.”

Thomas’s leadership will enhance BranchOut’s marketing strategy, helping to bring its cutting-edge GentleDry™ dehydrated snacks to a broader audience. As a pioneer in food innovation, BranchOut is leading the market with first-to-market, high-quality snack products made possible by its proprietary GentleDry™ technology. With a growing wholesale footprint and an exciting opportunity in DTC, the company is poised to redefine the shelf-stable snack category with superior taste, texture, and nutrition.

“I’m thrilled to join the BranchOut team and help take the brand to the next level,” said Thomas. “BranchOut’s breakthrough technology and commitment to creating best-in-class, high-quality snack products make this an exciting opportunity. I look forward to building a powerful direct-to-consumer channel that complements its already strong wholesale business.”

With multi-million-dollar commitments already in place from top retailers, ingredient buyers, and private label partners, BranchOut is positioned for sustained, high-margin revenue growth across all channels. As mentioned in our January 15 press release, BranchOut remains on track to being cash flow positive starting this quarter and reaching $9 million in revenue in H1 2025.

About BranchOut Food Inc.

BranchOut Food is a leading international food technology company, specializing in the production of high-quality dehydrated fruit and vegetable-based products through its proprietary GentleDry Technology. This next-generation dehydration method preserves up to 95% of the original nutrition of fresh produce, offering superior quality and taste. Protected by over 17 patents, BranchOut’s technology enables it to stand out as a trusted brand, ingredient and a private-label supplier. For more information, visit www.branchoutfood.com or follow us on social media here.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “position”, “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of BranchOut Food, Inc., (the Company) strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Investor Relations Contact:

Jeff Ramson, CEO

PCG Advisory, Inc.

[email protected]

SAN MATEO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation on denifanstat’s effect on triglycerides and LDL-cholesterol in advanced fibrosis patients will be delivered at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium being held February 23-26, 2025 in Banff, Canada. The presentation will feature lipidomic data from a post-hoc analysis of the Phase 2b FASCINATE-2 trial of denifanstat in MASH.

MASH Pathogenesis and Therapeutic Approaches Keystone Symposium:

Title:	Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study
Presenter:	Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences
Session:	Symposia Spotlight: Emerging Mechanisms
Date/Time:	Wednesday, February 26, 2025 at 3:00 PM MST
Location:	Fairmont Banff Springs, Banff, AB, Canada

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.

About MASH

Metabolic dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and to improve diagnostic clarity.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.

The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
Joyce Allaire
LifeSci Advisors 
[email protected]

LOS ANGELES, Feb. 19, 2025 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL” or the “Company”), a leader in innovative hearing protection, hearing enhancement, and Bluetooth^®/wireless technology, has entered into a multi-year licensing agreement with Feld Entertainment^® and Monster Jam^®, the most approachable, family-friendly motorsport in the world today, for a Monster Jam-branded hearing protection product portfolio.

Under the terms of the agreement, AXIL will produce and sell new adult and youth lines of Monster Jam-branded earbuds, earmuffs, hearing devices, and ear plugs in distribution channels in the United States. The new product lines will feature the signature AXIL sound quality, hearing protection, and enhancement functionality designed for fans of all ages. They are anticipated to be available for purchase in the spring of 2025 at various shops, retail outlets, and online platforms. 

“This new collaboration with Feld Entertainment for Monster Jam-branded hearing protection products reflects our commitment to superior hearing safety, while simultaneously capturing the energy and excitement of motorsports,” said AXIL CEO Jeff Toghraie. “Together, we can offer the millions of Monster Jam fans high-quality hearing protection, allowing them to fully enjoy the thrill of the event while safeguarding their hearing.”

Unexpected, unscripted, and unforgettable, Monster Jam features world-class athletes competing for championships on perfectly engineered dirt tracks that push these ever-evolving, state-of-the-art trucks to the limit. Beyond the 350 global live events each year, the Monster Jam brand extends off the track into the home through products, content, and merchandise that keeps the fun alive year-round.

“We are thrilled to be partnering with AXIL on a new line of Monster Jam-branded hearing protection,” said Jeff Bialosky, Senior Vice President of Global Partnerships and Licensing for Feld Entertainment. “Monster Jam fans are passionate about displaying their love for the sport, and through this partnership, they’ll now be able to showcase that fandom on earbuds, earmuffs, hearing devices, and ear plugs.”

About Feld Entertainment®

Feld Entertainment®, family owned and operated, is the worldwide leader in producing and presenting live touring family entertainment experiences that bring people together and uplift the human spirit. Properties include Ringling Bros. and Barnum & Bailey®, Monster Jam®, Disney On Ice, Monster Energy AMA Supercross, and the SuperMotocross World Championship. Across the brand portfolio, Feld Entertainment has entertained millions of families in more than 80 countries and on six continents. For more information, see www.feldentertainment.com.

About AXIL Brands

AXIL Brands (NYSE American: AXIL) is an emerging global consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL^® brand and premium hair and skincare products under its in-house Reviv3^® brand – selling products in the United States, Canada, the European Union, and throughout Asia.

To learn more, please visit the Company’s AXIL^® website at www.axilbrands.com and its Reviv3^® website at www.reviv3.com

Forward-Looking Statements

This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as “anticipate,” “believe,” “expect,” “continue,” “will,” “prepare,” “should,” and “focus,” among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management’s beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management’s control and may cause the Company’s results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) the Company’s ability to grow its net sales and operations, including developing new products and expanding internationally, and perform in accordance with any guidance; (ii) our ability to generate sufficient revenue to support the Company’s operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays the Company may experience in implementing its cost savings and efficiency initiatives; (iv) the Company’s ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of the Company’s customers, potentially increasing the negative impact to the Company by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which the Company operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase the Company product costs and other costs of doing business, and reduce the Company’s earnings; (vii) the Company’s ability to engage in strategic partnerships and expand its distribution and retail channels; and (viii) the impact of unstable market and general economic conditions on the Company’s business, financial condition and stock price, including inflationary cost pressures, the possibility of an economic recession and other macroeconomic factors, geopolitical events, and uncertainty, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and the Israel-Hamas conflict, and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, the Company does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Investor Relations:

Media Relations:
Todd McKnight
(917) 349-2175
[email protected]